We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-6.76%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$253M
Cap. Flow
-$52M
Cap. Flow %
-2.22%
Top 10 Hldgs %
44.73%
Holding
154
New
14
Increased
27
Reduced
18
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.7M
3
JNJ icon
Johnson & Johnson
JNJ
+$12.2M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$11M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.1M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$27.4M
2
A icon
Agilent Technologies
A
+$21.7M
3
CPHD
Cepheid Inc
CPHD
+$17.6M
4
LLY icon
Eli Lilly
LLY
+$16.4M
5
UNH icon
UnitedHealth
UNH
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Real Estate 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLLS
76
Cellectis
CLLS
$287M
$5.26M 0.22%
310,250
– –
DERM
77
DELISTED
Dermira, Inc.
DERM
$5.01M 0.21%
165,200
+82,600
+100% +$2.66M
MYOV
78
DELISTED
Myovant Sciences Ltd.
MYOV
$4.98M 0.21%
+400,000
New +$4.63M
EPZM
79
DELISTED
Epizyme, Inc
EPZM
$4.84M 0.21%
400,000
– –
KPTI icon
80
Karyopharm Therapeutics
KPTI
$159M
$4.7M 0.2%
33,355
– –
MNTA
81
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.61M 0.2%
306,600
+152,900
+99% +$2.02M
AGN.PRA
82
DELISTED
Allergan plc
AGN.PRA
$3.81M 0.16%
5,000
– –
ONC
83
BeOne Medicines Ltd
ONC
$33.4B
$3.54M 0.15%
116,707
– –
ACAD icon
84
Acadia Pharmaceuticals
ACAD
$4.55B
$3.22M 0.14%
111,800
– –
TVTX icon
85
Travere Therapeutics
TVTX
$5.33B
$3.18M 0.14%
167,949
-162,000
-49% -$3.31M
PRGO icon
86
Perrigo
PRGO
$1.43B
$3.1M 0.13%
37,300
– –
MNK
87
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$3.08M 0.13%
61,900
– –
BLUE
88
DELISTED
bluebird bio
BLUE
$3.04M 0.13%
3,809
– –
BHC icon
89
Bausch Health
BHC
$2.25B
$2.79M 0.12%
192,000
– –
SAGE
90
DELISTED
Sage Therapeutics
SAGE
$2.76M 0.12%
54,000
-92,800
-63% -$4.37M
GRFS
91
Grifois
GRFS
$5.58B
$2.67M 0.11%
166,000
– –
HZNP
92
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.64M 0.11%
162,900
-587,000
-78% -$10.6M
CHRS icon
93
Coherus Oncology
CHRS
$227M
$2.53M 0.11%
+90,000
New +$2.52M
AXDX
94
DELISTED
Accelerate Diagnostics
AXDX
$2.49M 0.11%
12,000
– –
THC icon
95
Tenet Healthcare
THC
$20.3B
$2.44M 0.1%
164,500
– –
ORKA
96
Oruka Therapeutics
ORKA
$5.9B
$2.31M 0.1%
3,756
– –
DBVT
97
DBV Technologies
DBVT
$817M
$2.31M 0.1%
6,560
– –
ADAP
98
DELISTED
Adaptimmune Therapeutics
ADAP
$2.29M 0.1%
566,368
– –
ELGX
99
DELISTED
Endologix Inc
ELGX
$2.21M 0.09%
38,675
-38,675
-50% -$3.54M
ACHC icon
100
Acadia Healthcare
ACHC
$2.62B
$2.15M 0.09%
64,900
+29,700
+84% +$1.15M
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Tekla Capital Management held 154 positions worth $2.35B, down 9.7% from $2.6B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q4 2016 filing shows 14 new, 27 increased, 18 reduced and 11 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M. The largest sale was Alkermes, an estimated $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2016 buy was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M.
  • Tekla Capital Management added most to Biogen in Q4 2016, an estimated $16.4M increase.
  • Tekla Capital Management's biggest Q4 2016 reduction was Eli Lilly, cutting an estimated $16.4M.
  • Tekla Capital Management fully exited Alkermes in Q4 2016, selling an estimated $27.4M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.35B portfolio in Q4 2016.
  • Tekla Capital Management opened 14 new positions and closed 11 in Q4 2016.
  • Tekla Capital Management's portfolio value fell 9.7% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.